Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Catalytic Neuroprotective Mechanism Of Action
Portfolio Pulse from Benzinga Newsdesk
Clene Inc. (NASDAQ:CLNN) announced the publication of a scientific paper describing the catalytic mechanism of action of its investigational drug CNM-Au8. The study demonstrates that the neuroprotective properties of CNM-Au8 can be attributed to its therapeutic catalytic activity. The drug is being investigated as a potential treatment for multiple neurodegenerative diseases, including ALS, MS, and Parkinson's disease.
September 28, 2023 | 12:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The publication of the scientific paper could boost investor confidence in Clene Inc. as it provides evidence of the potential effectiveness of its investigational drug CNM-Au8.
The publication of a scientific paper on the mechanism of action of CNM-Au8 provides evidence of the drug's potential effectiveness. This could increase investor confidence in Clene Inc. and its ability to develop effective treatments for neurodegenerative diseases, potentially leading to a short-term increase in the company's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100